Description: The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Category: China Region
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock non-US | 90.54 | 0.00 | 90.54 |
| Stock US | 9.31 | 0.00 | 9.31 |
| Cash | 0.22 | 0.07 | 0.15 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 99.78 | 8.08 |
| Communication Services | 0.22 | 14.92 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| Asia Emerging | 84.69 | 86.05 |
| North America | 9.32 | 0.19 |
| Asia Developed | 5.99 | 13.55 |
| Australasia | 0.00 | 0.04 |
| Latin America | 0.00 | 0.09 |
| United Kingdom | 0.00 | 0.06 |
| Europe Developed | 0.00 | 0.02 |